For patients with unknown EGFR status mutations, the first step should be to get the material for EGFR gene testing as much as possible. This is the first important thing to increase the importance of this area. In addition, we may need to improve the current low detection rate in terms of survival. We conducted a study before the meeting, and more than 200 participants came to the meeting, about 50% of the hospitals are still in this situation, giving TKI treatment to patients with unknown EGFR. In addition, more hospitals should be allowed to carry out routine EGFR testing, and quality control should be ensured in particular. The second aspect is that if the patient still cannot detect EGFR mutation, for example, a patient with recurrent metastasis, the specimen in the past is too small or lost, in this case, there is a great difficulty in taking the material now, this situation is still common in our clinical practice, the consensus reached today is that the two-drug combination chemotherapy regimen (platinum-containing two-drug combination chemotherapy regimen) should be preferred, this reached The consensus at the panel level was 86% of the physicians agreed. Of the 280 doctors in the room, 89% agreed that the platinum-containing two-drug combination regimen should be preferred. So what’s the problem with choosing a TKI? When the EGFR mutation status is unknown, the available data demonstrate that the efficiency of TKI selection is very low, which means that the remission rate is very low, and that there are risks associated with treatment in these patients.